Clinical Trials Directory

Trials / Unknown

UnknownNCT05564884

Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery

The Association of Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery With Infant COVID-19 Infection Under Age 6 Months: a Prospective Cohort Study

Status
Unknown
Phase
Study type
Observational
Enrollment
58 (estimated)
Sponsor
Rabin Medical Center · Academic / Other
Sex
Female
Age
Healthy volunteers

Summary

To assess the association between neonatal SARS-CoV-2 antibody level at delivery and infant COVID-19 infection under age 6 months, and to identify predictive factors for neonatal antibody level at delivery.

Detailed description

This prospective observational study was conducted at the Rabin Medical Center, Israel. Mothers were enrolled from September 2021 to mid-February 2022, prior to transfer to the delivery room, and followed at the Maternity and Infant Ward. The study was approved by the institutional ethics committee (RMC- 0275-21). Written informed consent was obtained from the participating mothers. Inclusion criteria included maternal recipient of at least one dose of the BNT162b2 mRNA COVID-19 vaccine or prior microbiologically-confirmed natural COVID-19 infection. Exclusion criteria included (a) preterm birth at \<34 weeks gestation; (b) congenital or acquired immune deficiency, including recipient of biological agents during the prior year to enrolment.

Conditions

Interventions

TypeNameDescription
OTHERno intervantionno intervention

Timeline

Start date
2021-09-12
Primary completion
2022-02-24
Completion
2022-11-01
First posted
2022-10-04
Last updated
2022-10-04

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT05564884. Inclusion in this directory is not an endorsement.